The ketogenic diet in patients with myoclonic status in non-progressive encephalopathy

Roberto Caraballo1, Francesca Darra2, Gabriela Reyes1

  • 1Department of Neurology, Hospital de Pediatría "Prof Dr Juan P Garrahan", Buenos Aires, Argentina.

Seizure
|July 26, 2017
PubMed

Insights

The ketogenic diet (KD) shows promise for treating myoclonic status in non-progressive encephalopathy (MSNPE). Six infants experienced significant seizure reduction, with some seeing complete disappearance of symptoms and improved quality of life.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Nutritional Neuroscience

Background:

  • Myoclonic status in non-progressive encephalopathy (MSNPE) involves prolonged seizures and developmental impairments in infants.
  • Refractory epileptic encephalopathies often prompt exploration of alternative treatments like the ketogenic diet (KD).

Purpose of the Study:

  • To evaluate the efficacy of the ketogenic diet (KD) as a treatment for MSNPE.
  • To assess the tolerability and safety of the KD in this pediatric patient group.

Main Methods:

  • A cohort of 99 patients diagnosed with MSNPE were identified between 1980 and 2013.
  • Six patients were initiated on the KD following the Hopkins protocol and monitored for at least 24 months.

Main Results:

  • After 12 months, 5 out of 6 patients achieved over 50% seizure reduction.
  • Myoclonic status epilepticus resolved within 6 months in patients with significant seizure reduction.
  • The KD demonstrated excellent tolerability with no adverse events reported; antiepileptic drug (AED) dosages were reduced in most patients.

Conclusions:

  • The ketogenic diet (KD) presents a promising therapeutic option for managing MSNPE.
  • Significant seizure reduction and improvements in cognitive performance and quality of life were observed in responders.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
853
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
950